Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted strong financial performance with record revenue and net income, a raised revenue guidance for 2025, and significant product sales growth. Despite some uncertainties in product development and strategic collaborations, the market reacted positively to the optimistic guidance and financial discipline. The Q&A revealed management's cautious optimism and focus on strategic growth, without major negative surprises. Given the company's small-cap status, the positive financial results and guidance are likely to drive a stock price increase in the short term.
Key Financial Performance
Total Revenue $69.5 million, including record net product sales of $64.1 million, a 65% year-over-year increase. The increase was driven by improved patient affordability, new patients, and favorable gross-to-net dynamics.
Net Income $27.9 million, compared to $12.4 million in the same period of 2024. The increase was due to strong revenue growth and financial discipline.
Cash Balance $137.1 million, compared to $77.3 million at the end of 2024. The increase reflects strong financial performance and revenue growth.
TAVALISSE Net Product Sales $44.7 million, a 70% year-over-year increase. Growth was driven by increased demand and favorable gross-to-net dynamics.
GAVRETO Net Product Sales $11.1 million, a 56% year-over-year increase. Growth was driven by an increase in new patients and carryover demand.
REZLIDHIA Net Product Sales $8.3 million, a 50% year-over-year increase. Growth was driven by record demand and an increase in both breadth and depth of prescribers.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
R289 Phase Ib Study: Enrollment for the dose escalation phase is complete, and data will be presented at the ASH Annual Meeting. The dose expansion phase has begun to determine the recommended dose for future studies.
Olutasidenib Expansion: Four posters on mutant IDH1 AML will be presented at ASH. A fifth study with MD Anderson opened in September, and the first patient was enrolled in the CONNECT Phase II TarGeT-D study for high-grade glioma in October.
Global Expansion of TAVALISSE: TAVALISSE is now available in Japan, Europe, Canada, Israel, and South Korea through partnerships. Regulatory approvals are being pursued in additional markets.
REZLIDHIA Expansion: Expanded relationship with Kissei for several Asian countries and a licensing agreement with Dr. Reddy's for broader access.
Revenue Growth: Total revenue for Q3 2025 was $69.5 million, with net product sales of $64.1 million, a 65% year-over-year increase. Year-to-date net product sales surpassed 2024 full-year sales.
Financial Discipline: Generated $27.9 million in net income for Q3 and increased cash balance to $137.1 million. Raised 2025 revenue guidance to $285-$290 million.
In-licensing and Acquisitions: Rigel is pursuing additional in-licensing deals or asset acquisitions to align with its hematology and oncology focus.
Collaboration with MyeloMATCH: Planning a study to evaluate olutasidenib in first-line AML and MDS.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Product Development Risks: The company acknowledges that forward-looking statements regarding financial outlook and plans for regulatory and product development are subject to risks and uncertainties that may cause actual results to differ from forecasts.
Clinical Trial Risks: The ongoing Phase Ib study of R289 and other clinical trials face risks such as patient enrollment challenges, potential delays, and uncertainties in achieving desired outcomes, which could impact future studies and regulatory approvals.
Strategic Collaboration Risks: Collaborations with MD Anderson, CONNECT, and MyeloMATCH involve uncertainties, including the success of joint studies and the ability to achieve desired outcomes in new therapeutic areas.
Supply Chain and Market Expansion Risks: Efforts to expand access to products in international markets depend on regulatory approvals and partnerships, which may face delays or challenges.
Financial Risks: While the company has demonstrated strong financial performance, reliance on continued revenue growth and financial discipline is critical to fund development programs and achieve long-term growth.
Competitive Pressures: The company operates in a competitive market, and the success of its products depends on differentiation and market acceptance, particularly for products like TAVALISSE, GAVRETO, and REZLIDHIA.
Product Development and Commercialization Risks: The success of new products like R289 and olutasidenib depends on achieving clinical milestones, regulatory approvals, and market acceptance, which are uncertain.
Partnership Termination Risks: The termination of the CNS disease program with Eli Lilly highlights risks associated with partnerships, which could impact future opportunities and revenue streams.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: Rigel has raised its total revenue guidance for 2025 to approximately $285 million to $290 million, up from the prior range of $270 million to $280 million. This includes updated net product sales expectations of approximately $225 million to $230 million, an increase from the prior range of $210 million to $220 million.
Growth Projections: The company expects total revenue growth of 55% to 59% in 2025 compared to 2024, exceeding the average growth rate of 32% over the last four years.
R289 Development: Rigel is advancing its Phase Ib study of R289, a dual IRAK1 and IRAK4 inhibitor, in patients with relapsed or refractory lower-risk MDS. The dose escalation phase is complete, and updated data will be presented at the ASH Annual Meeting in December. The dose expansion phase is ongoing, and a recommended Phase II dose decision is expected in the second half of 2026.
Olutasidenib Expansion: Strategic collaborations are underway to evaluate olutasidenib in additional therapeutic areas, including IDH1 mutation-positive AML, MDS, and glioma. A new study with MyeloMATCH is planned, and Rigel is considering a Rigel-led study in glioma.
Commercial Product Growth: Rigel aims to increase sales of its commercial products, including TAVALISSE, GAVRETO, and REZLIDHIA, to achieve its updated revenue and profit guidance for 2025.
In-Licensing and Acquisitions: The company is evaluating new in-licensing and product acquisition opportunities to expand its product portfolio with synergistic late-stage assets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How does the company see the competitive positioning of R289 in lower-risk MDS versus RYTELO?
A:The company believes it is too early to speculate on the competitive positioning. They are in a different patient population compared to imetelstat, with patients more heavily pretreated and having received HMAs. They are pleased with the preliminary activity and safety profile of R289. Plans for a registration study will be decided after dose expansion and further data collection.
Q:What are the company's views on the potential for priority review for R289?
A:The company acknowledges the potential for priority review due to the Fast Track designation. However, they will need to see how the data evolves in the dose expansion part of the study before making further comments.
Q:What benchmarks are being considered for the CONNECT study in glioma with IDH1 mutations?
A:The company states that this is a novel approach involving maintenance therapy post-chemo radiation. The comparison will be versus a historical control, and there is no specific data for this maintenance setting.
Q:What was the Q3 gross to net rate by brand, and what are the expected Q1 and Q4 rates?
A:The company has not provided specific guidance on gross to net rates by product. They mentioned favorable gross to net dynamics due to patient affordability and efficiency improvements in patient services and distribution networks.
Q:What are the expectations for the updated data at ASH for R289 in lower-risk MDS patients?
A:The company plans to present data with a cutoff date of October 28, including 16 weeks of follow-up for all patients in the 500-milligram BID dose level. They are eager to share this data.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to several questions. For example, they did not provide specific guidance on gross to net rates by product, citing various factors without detailed breakdowns. Additionally, they refrained from speculating on the competitive positioning of R289 in lower-risk MDS and the benchmarks for the CONNECT study in glioma, offering only general comments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASH meeting
Executive VP
GAVRETO REZLIDHIA
Grifols Medison
IDH AML
IIa
MDS AML
MyeloMATCH olutasidenib
Phase II
Slide product
Sunday
VP Chief
collaboration olutasidenib
date increase
development term
dose study
dynamic
enrollment escalation
escalation study
imetelstat
increase product
licensing
line AML
need therapy
olutasidenib IDH
olutasidenib area
olutasidenib combination
olutasidenib patient
patient CONNECT
patient ESAs
patient IDH
patient expansion
poster
presentation ASH
record product
sale date
study olutasidenib
study presentation
therapy disease
use olutasidenib
RIGL Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call highlights strong financial performance with significant year-over-year sales growth across key products, despite a slight net income decline due to higher R&D and operational expenses. The Q&A section reveals management's strategic focus on hematology/oncology, with promising developments for R289. Although some details were unclear, the overall sentiment is positive, supported by a robust revenue increase and strategic product focus. Given the company's small-cap status, the stock is likely to react positively, falling into the 2% to 8% range over the next two weeks.
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call indicates strong financial performance with significant revenue and net income growth, a raised revenue guidance for 2025, and strategic product development plans. Despite some uncertainties in global market access and management's vague responses in the Q&A, the overall sentiment is positive due to the raised guidance and strong financial metrics. The market cap suggests a moderate reaction, leading to a predicted stock price movement of 2% to 8%.
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlighted strong financial performance with record revenue and net income, a raised revenue guidance for 2025, and significant product sales growth. Despite some uncertainties in product development and strategic collaborations, the market reacted positively to the optimistic guidance and financial discipline. The Q&A revealed management's cautious optimism and focus on strategic growth, without major negative surprises. Given the company's small-cap status, the positive financial results and guidance are likely to drive a stock price increase in the short term.
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call reveals strong financial performance with a 76% increase in net product sales and a significant net income turnaround. The company's strategic partnerships and product demand growth, particularly for GAVRETO, are positive indicators. Despite some risks in strategic execution and global expansion, the optimistic guidance and financial discipline suggest a positive stock price movement. The market cap indicates a potential for notable reaction, but not extreme, leading to a 'Positive' sentiment.
RIGL Slides
RIGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
